Advances in induced pluripotent stem cell research for neurological diseases
-
- Ito Daisuke
- Department of Neurology, School of Medicine, Keio University
-
- Yagi Takuya
- Department of Neurology, School of Medicine, Keio University
-
- Nihei Yoshihiro
- Department of Neurology, School of Medicine, Keio University
-
- Yoshizaki Takahito
- Department of Neurology, School of Medicine, Keio University
-
- Suzuki Norihiro
- Department of Neurology, School of Medicine, Keio University
Bibliographic Information
- Other Title
-
- 神経疾患におけるiPS細胞研究の現状と展望
- シンケイ シッカン ニ オケル iPS サイボウ ケンキュウ ノ ゲンジョウ ト テンボウ
Search this article
Abstract
In 2006, Takahashi and Yamanaka reported a groundbreaking study showing mouse and human somatic cells that can be reprogrammed to the pluripotent state by expression of only a few transcription factors (Oct4, Sox2, Klf4, and c-Myc). This novel strategy can be used for transplantation therapies without immune rejection providing additional advantages regarding ethic issues of oocyte donation. For neurological diseases, disease-specific induced pluripotent stem (iPS) cells may serve as an invaluable model for clarifying pathogenesis and for screening new drug therapies. In particular, differentiated neurons derived from patient iPS cells could infinitely provide an alternative cellular-biochemical material for research instead of biopsy and autopsy. This review summarizes the current studies applying iPS cells in the field of neurology and discusses their potential and limitations for therapy against neurological diseases.<br>
Journal
-
- Rinsho Shinkeigaku
-
Rinsho Shinkeigaku 50 (7), 449-454, 2010
Societas Neurologica Japonica
- Tweet
Details 詳細情報について
-
- CRID
- 1390001205036660608
-
- NII Article ID
- 10026525603
- 130004504772
-
- NII Book ID
- AN00253207
-
- ISSN
- 18820654
- 0009918X
-
- NDL BIB ID
- 10773597
-
- PubMed
- 20681260
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- Abstract License Flag
- Disallowed